More about

Lymphoma

News
May 26, 2023
2 min watch
Save

VIDEO: Considerations when treating relapsed, refractory DLBCL

VIDEO: Considerations when treating relapsed, refractory DLBCL

In this video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses the use of cellular therapy in patients with relapsed/refractory Lymphoma.

News
May 26, 2023
1 min watch
Save

VIDEO: Awareness of cell therapy, ‘novel therapeutics’ in DLBCL benefits patients, providers

VIDEO: Awareness of cell therapy, ‘novel therapeutics’ in DLBCL benefits patients, providers

In a video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses who benefits from awareness surrounding DLBCL.

News
May 19, 2023
2 min read
Save

FDA approves Epkinly for treatment of advanced diffuse large B-cell lymphoma

FDA approves Epkinly for treatment of advanced diffuse large B-cell lymphoma

The FDA granted accelerated approval to epcoritamab-bysp for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.

CME
Multimedia

Real-World Perspectives in Managing CLL Treatment

Real-World Perspectives in Managing CLL Treatment
0.75 CME
45 MINS
$0 FEE
News
May 07, 2023
4 min watch
Save

AYA cancer survivors treated with cardiotoxic therapies exhibit accelerated cardiac aging

AYA cancer survivors treated with cardiotoxic therapies exhibit accelerated cardiac aging

Adolescent and young adult cancer survivors who received cardiotoxic treatments exhibited a high burden of poor cardiac function, according to study results presented at American Association for Cancer Research Annual Meeting.

News
April 25, 2023
3 min read
Save

Bispecific CAR-T induces durable responses in advanced non-Hodgkin lymphoma

Bispecific CAR-T induces durable responses in advanced non-Hodgkin lymphoma

Ten of 11 patients with relapsed or refractory B-cell lymphoma achieved objective response to an investigational dual-target chimeric antigen receptor T-cell therapy, according to study results.

News
April 20, 2023
8 min read
Save

Man presents with unilateral blurry vision

Man presents with unilateral blurry vision

A 56-year-old white man was referred to the uveitis clinic at the New England Eye Center by an outside ophthalmologist for sudden-onset painless vision loss that started 2 months before presentation.

News
April 19, 2023
1 min read
Save

FDA approves Polivy regimen for previously untreated diffuse large B-cell lymphoma

FDA approves Polivy regimen for previously untreated diffuse large B-cell lymphoma

The FDA approved polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin and prednisone as first-line therapy for patients with certain types of B-cell lymphoma.

News
April 17, 2023
2 min read
Save

Presence of CVD, especially atherosclerosis, could increase cancer risk

Presence of CVD, especially atherosclerosis, could increase cancer risk

Cardiovascular disease, especially atherosclerotic CVD, was associated with increased risk for cancer diagnosis, according to a study published in JACC: CardioOncology.

News
April 13, 2023
3 min read
Save

Despite access barriers, physicians prefer CAR-T for treatment of advanced B-cell lymphoma

Despite access barriers, physicians prefer CAR-T for treatment of advanced B-cell lymphoma

Physicians recommended chimeric antigen receptor T-cell therapy more frequently than any other regimen for third-line treatment of relapsed or refractory diffuse large B-cell lymphoma, survey results showed.

View more